A triple drug approach that blocks the KRAS pathway at three points eliminated pancreatic tumors and prevented resistance in ...

Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...

This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research.

A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors. Using an experimental therapy to target microscopic ...

Roche Holdings AG on Monday shared results from the phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients. Trial Misses Primary Goal The trial ...

Scientists at Oregon Health & Science University have developed a new molecule that could open the door to treating triple-negative breast cancer, one of the most aggressive and difficult-to-treat ...

Nanomedicine is rapidly transforming the landscape of cancer treatment through the development of advanced drug-delivery carriers. Despite notable progress ...

Over the past decade, however, a wave of technological advances has begun to expand the druggable proteome. These include covalent inhibitors (such as sotorasib), chemical proteomics, and AI-enabled ...

The U.S. Food and Drug Administration today announced another major step in its initiative to streamline the development of biosimilar medicines, ...

Ipsen telegraphed plans to acquire Epizyme and the FDA-approved Tazverik in June 2022, two years after the med’s clearance in the U.S. as both an epithelioid sarcoma and follicular lymphoma treatment.

A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told ...